共 50 条
- [41] Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)BLOOD, 2015, 126 (23)Hochhaus, AndreasSaglio, GiuseppeHughes, Timothy P.Larson, Richard A.Taningco, LiliaDeng, WeipingMenssen, Hans D.Kantarjian, Hagop M.
- [42] Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective AnalysisBLOOD, 2018, 132Iriyama, NoriyoshiSugimoto, Kei-JiSato, ErikoTakaku, TomoikuTokuhira, MichihideNakazato, TomonoriIshikawa, MahoFujita, HiroyukiKimura, YutaFujioka, IsaoAsou, NorioKizaki, MasahiroKomatsu, NorioHatta, YoshihiroKawaguchi, Tatsuya
- [43] Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysisMedical Oncology, 2018, 35Noriyoshi IriyamaKei-Ji SugimotoEriko SatoTomoiku TakakuMichihide TokuhiraTomonori NakazatoMaho IshikawaHiroyuki FujitaIsao FujiokaYuta KimuraNorio AsouMasahiro KizakiNorio KomatsuYoshihiro HattaTatsuya Kawaguchi
- [44] Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysisMEDICAL ONCOLOGY, 2018, 35 (11)Iriyama, NoriyoshiSugimoto, Kei-JiSato, ErikoTakaku, TomoikuTokuhira, MichihideNakazato, TomonoriIshikawa, MahoFujita, HiroyukiFujioka, IsaoKimura, YutaAsou, NorioKizaki, MasahiroKomatsu, NorioHatta, YoshihiroKawaguchi, Tatsuya
- [45] An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase (vol 143, pg 2059, 2017)JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (01) : 187 - 188Luis Steegmann, JuanColomer, DolorsGomez-Casares, Maria-TeresaGarcia-Gutierrez, ValentinOrti, GuillermoRamirez-Payer, AngelOlavarria, EduardoVall-llovera, FerranGiraldo, PilarConde, EulogioVallansot, RolandoLuis Lopez-Lorenzo, JosePalomera, LuisAlvarez-Larran, AlbertoConesa, VenancioBautista, GuiomarCasas, LauraGiles, FrankHochhaus, AndreasFelipe Casado-Montero, Luis
- [46] Cost-effectiveness of nilotinib versus imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph plus ) chronic myeloid leukemia in the chronic phase (CML-CP): Swedish perspectiveJOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Ovanfors, A.Stephens, J.Snedecor, S. J.Patel, D.Ji, X.Carpiuc, K. T.Coombs, J.Botteman, M.
- [47] COST-EFFECTIVENESS OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) IN RUSSIAN FEDERATIONVALUE IN HEALTH, 2012, 15 (07) : A426 - A426Yagudina, R.Kulikov, A.Komarov, I
- [48] BUDGET IMPACT ANALYSIS FOR THE FIRST-LINE AND SECOND-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIAVALUE IN HEALTH, 2016, 19 (03) : A244 - A245Lachaine, J.Kouroukis, C. T.
- [49] BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZILVALUE IN HEALTH, 2009, 12 (07) : A262 - A262Asano, E.Nita, M.Moellmann-Coelho, A.Rached, R.Donato, B.Rahal, E.
- [50] Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim AnalysisBLOOD, 2014, 124 (21)Hughes, Timothy P.Munhoz, Eduardo CiliaoElhaddad, AlaaChuan, Ong TeeAbdulkadyrov, KudratShortt, JakeQuach, HangPavlovsky, CarolinaLouw, Vernon J.Meillon, LuisShih, Lee-YungTurkina, Anna G.Hwang, JonathanNidamarthy, Prasanna KumarDalal, DarshanLipton, Jeffrey H.